Equities

Dishman Carbogen Amcis Ltd

Dishman Carbogen Amcis Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)189.50
  • Today's Change-3.97 / -2.05%
  • Shares traded427.08k
  • 1 Year change+23.94%
  • Beta1.7977
Data delayed at least 15 minutes, as of Nov 08 2024 10:26 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments4,3143,0884,028
Total Receivables, Net5,5207,1276,928
Total Inventory8,8298,0386,451
Prepaid expenses567357362
Other current assets, total53574619
Total current assets19,28219,18418,387
Property, plant & equipment, net32,32032,27127,869
Goodwill, net39,10738,63836,457
Intangibles, net2,2311,3551,151
Long term investments1,024966588
Note receivable - long term1,6671,8751,802
Other long term assets6810284
Total assets95,81494,53586,375
LIABILITIES
Accounts payable2,4412,1971,934
Accrued expenses1,4951,4451,203
Notes payable/short-term debt16,2026,8084,926
Current portion long-term debt/capital leases1,6021,5772,271
Other current liabilities, total3,8075,9563,864
Total current liabilities25,54717,98414,198
Total long term debt5,32213,70411,102
Total debt23,12622,08918,299
Deferred income tax3937491,286
Minority interest------
Other liabilities, total8,2774,0024,300
Total liabilities39,53936,43830,885
SHAREHOLDERS EQUITY
Common stock314314314
Additional paid-in capital47,38847,38847,388
Retained earnings (accumulated deficit)1,7134,4184,204
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total6,8615,9783,585
Total equity56,27558,09755,489
Total liabilities & shareholders' equity95,81494,53586,375
Total common shares outstanding157157157
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.